Neuland Laboratories Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 27, 2025, 12:57 pm

Quick Insight

Neuland Laboratories Ltd, a pharmaceutical company, currently trades at a price of ₹13,171 with a market capitalization of ₹16,898 Cr. Despite a high P/E ratio of 128, the company shows a respectable ROE of 14.8% and ROCE of 18.7%. Operating profit margin stands at 12%, with a net profit of ₹260 Cr. Notably, the company holds reserves worth ₹1,512 Cr, but carries borrowings of ₹157 Cr, resulting in a comfortable interest coverage ratio of 33.94x. With a price-to-book value of 6.32x and a CCC of 160 days, Neuland Laboratories presents a financially robust profile, suggesting potential for growth and value appreciation in the pharmaceutical industry.

Competitors of Neuland Laboratories Ltd

All Competitor Stocks of Neuland Laboratories Ltd

Quarterly Result

Last Updated: August 1, 2025, 4:25 pm

Below is a detailed analysis of the quarterly data for Neuland Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 293.00 Cr.. The value appears to be declining and may need further review. It has decreased from 328.00 Cr. (Mar 2025) to 293.00 Cr., marking a decrease of 35.00 Cr..
• For Expenses, as of Jun 2025, the value is 258.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 277.00 Cr. (Mar 2025) to 258.00 Cr., marking a decrease of 19.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 34.00 Cr.. The value appears to be declining and may need further review. It has decreased from 51.00 Cr. (Mar 2025) to 34.00 Cr., marking a decrease of 17.00 Cr..
• For OPM %, as of Jun 2025, the value is 12.00%. The value appears to be declining and may need further review. It has decreased from 16.00% (Mar 2025) to 12.00%, marking a decrease of 4.00%.
• For Other Income, as of Jun 2025, the value is 8.00 Cr.. The value appears strong and on an upward trend. It has increased from 7.00 Cr. (Mar 2025) to 8.00 Cr., marking an increase of 1.00 Cr..
• For Interest, as of Jun 2025, the value is 5.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Mar 2025) to 5.00 Cr., marking an increase of 3.00 Cr..
• For Depreciation, as of Jun 2025, the value is 20.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17.00 Cr. (Mar 2025) to 20.00 Cr., marking an increase of 3.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Mar 2025) to 18.00 Cr., marking a decrease of 21.00 Cr..
• For Tax %, as of Jun 2025, the value is 21.00%. The value appears to be improving (decreasing) as expected. It has decreased from 29.00% (Mar 2025) to 21.00%, marking a decrease of 8.00%.
• For Net Profit, as of Jun 2025, the value is 14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 14.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 10.83. The value appears to be declining and may need further review. It has decreased from 21.68 (Mar 2025) to 10.83, marking a decrease of 10.85.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: July 22, 2025, 3:18 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 2:41 pm

Below is a detailed analysis of the balance sheet data for Neuland Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 13.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,512.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,270.00 Cr. (Mar 2024) to 1,512.00 Cr., marking an increase of 242.00 Cr..
• For Borrowings, as of Mar 2025, the value is 157.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 95.00 Cr. (Mar 2024) to 157.00 Cr., marking an increase of 62.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 498.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 454.00 Cr. (Mar 2024) to 498.00 Cr., marking an increase of 44.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,180.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,833.00 Cr. (Mar 2024) to 2,180.00 Cr., marking an increase of 347.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 955.00 Cr.. The value appears strong and on an upward trend. It has increased from 824.00 Cr. (Mar 2024) to 955.00 Cr., marking an increase of 131.00 Cr..
• For CWIP, as of Mar 2025, the value is 48.00 Cr.. The value appears strong and on an upward trend. It has increased from 46.00 Cr. (Mar 2024) to 48.00 Cr., marking an increase of 2.00 Cr..
• For Investments, as of Mar 2025, the value is 109.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2024) to 109.00 Cr., marking an increase of 108.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,068.00 Cr.. The value appears strong and on an upward trend. It has increased from 962.00 Cr. (Mar 2024) to 1,068.00 Cr., marking an increase of 106.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,180.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,833.00 Cr. (Mar 2024) to 2,180.00 Cr., marking an increase of 347.00 Cr..

Notably, the Reserves (1,512.00 Cr.) exceed the Borrowings (157.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Neuland Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 24, the value is 233.89. This value is within the healthy range. It has increased from 127.45 (Mar 23) to 233.89, marking an increase of 106.44.
• For Diluted EPS (Rs.), as of Mar 24, the value is 233.89. This value is within the healthy range. It has increased from 127.45 (Mar 23) to 233.89, marking an increase of 106.44.
• For Cash EPS (Rs.), as of Mar 24, the value is 278.89. This value is within the healthy range. It has increased from 167.66 (Mar 23) to 278.89, marking an increase of 111.23.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 993.65. It has increased from 769.94 (Mar 23) to 993.65, marking an increase of 223.71.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 994.31. It has increased from 770.59 (Mar 23) to 994.31, marking an increase of 223.72.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 1,208.16. It has increased from 923.37 (Mar 23) to 1,208.16, marking an increase of 284.79.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 368.31. This value is within the healthy range. It has increased from 218.28 (Mar 23) to 368.31, marking an increase of 150.03.
• For PBIT / Share (Rs.), as of Mar 24, the value is 322.03. This value is within the healthy range. It has increased from 177.37 (Mar 23) to 322.03, marking an increase of 144.66.
• For PBT / Share (Rs.), as of Mar 24, the value is 311.18. This value is within the healthy range. It has increased from 167.24 (Mar 23) to 311.18, marking an increase of 143.94.
• For Net Profit / Share (Rs.), as of Mar 24, the value is 232.61. This value is within the healthy range. It has increased from 126.75 (Mar 23) to 232.61, marking an increase of 105.86.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 232.61. This value is within the healthy range. It has increased from 126.75 (Mar 23) to 232.61, marking an increase of 105.86.
• For PBDIT Margin (%), as of Mar 24, the value is 30.48. This value is within the healthy range. It has increased from 23.63 (Mar 23) to 30.48, marking an increase of 6.85.
• For PBIT Margin (%), as of Mar 24, the value is 26.65. This value exceeds the healthy maximum of 20. It has increased from 19.20 (Mar 23) to 26.65, marking an increase of 7.45.
• For PBT Margin (%), as of Mar 24, the value is 25.75. This value is within the healthy range. It has increased from 18.11 (Mar 23) to 25.75, marking an increase of 7.64.
• For Net Profit Margin (%), as of Mar 24, the value is 19.25. This value exceeds the healthy maximum of 10. It has increased from 13.72 (Mar 23) to 19.25, marking an increase of 5.53.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is 19.25. This value is within the healthy range. It has increased from 13.72 (Mar 23) to 19.25, marking an increase of 5.53.
• For Return on Networth / Equity (%), as of Mar 24, the value is 23.40. This value is within the healthy range. It has increased from 16.46 (Mar 23) to 23.40, marking an increase of 6.94.
• For Return on Capital Employeed (%), as of Mar 24, the value is 29.57. This value is within the healthy range. It has increased from 20.05 (Mar 23) to 29.57, marking an increase of 9.52.
• For Return On Assets (%), as of Mar 24, the value is 16.37. This value is within the healthy range. It has increased from 10.35 (Mar 23) to 16.37, marking an increase of 6.02.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.03. This value is below the healthy minimum of 0.2. It has decreased from 0.07 (Mar 23) to 0.03, marking a decrease of 0.04.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.06. This value is within the healthy range. It has decreased from 0.12 (Mar 23) to 0.06, marking a decrease of 0.06.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.91. It has increased from 0.80 (Mar 23) to 0.91, marking an increase of 0.11.
• For Current Ratio (X), as of Mar 24, the value is 2.15. This value is within the healthy range. It has increased from 1.73 (Mar 23) to 2.15, marking an increase of 0.42.
• For Quick Ratio (X), as of Mar 24, the value is 1.33. This value is within the healthy range. It has increased from 1.10 (Mar 23) to 1.33, marking an increase of 0.23.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 2.01. This value is below the healthy minimum of 4. It has increased from 1.79 (Mar 23) to 2.01, marking an increase of 0.22.
• For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 4.27. This value is below the healthy minimum of 20. It has increased from 3.92 (Mar 23) to 4.27, marking an increase of 0.35.
• For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 3.56. This value is below the healthy minimum of 20. It has increased from 2.96 (Mar 23) to 3.56, marking an increase of 0.60.
• For Earning Retention Ratio (%), as of Mar 24, the value is 95.73. This value exceeds the healthy maximum of 70. It has decreased from 96.08 (Mar 23) to 95.73, marking a decrease of 0.35.
• For Cash Earning Retention Ratio (%), as of Mar 24, the value is 96.44. This value exceeds the healthy maximum of 70. It has decreased from 97.04 (Mar 23) to 96.44, marking a decrease of 0.60.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 33.94. This value is within the healthy range. It has increased from 21.55 (Mar 23) to 33.94, marking an increase of 12.39.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 22.44. This value is within the healthy range. It has increased from 13.51 (Mar 23) to 22.44, marking an increase of 8.93.
• For Enterprise Value (Cr.), as of Mar 24, the value is 8,068.90. It has increased from 2,383.79 (Mar 23) to 8,068.90, marking an increase of 5,685.11.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 5.18. This value exceeds the healthy maximum of 3. It has increased from 2.00 (Mar 23) to 5.18, marking an increase of 3.18.
• For EV / EBITDA (X), as of Mar 24, the value is 16.98. This value exceeds the healthy maximum of 15. It has increased from 8.47 (Mar 23) to 16.98, marking an increase of 8.51.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 5.20. This value exceeds the healthy maximum of 3. It has increased from 1.95 (Mar 23) to 5.20, marking an increase of 3.25.
• For Retention Ratios (%), as of Mar 24, the value is 95.72. This value exceeds the healthy maximum of 70. It has decreased from 96.07 (Mar 23) to 95.72, marking a decrease of 0.35.
• For Price / BV (X), as of Mar 24, the value is 6.32. This value exceeds the healthy maximum of 3. It has increased from 2.34 (Mar 23) to 6.32, marking an increase of 3.98.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 5.20. This value exceeds the healthy maximum of 3. It has increased from 1.95 (Mar 23) to 5.20, marking an increase of 3.25.
• For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 23) to 0.03, marking a decrease of 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness